Neofollin (Estradiol Valerate)

Neofollin, an estrogen replacement therapy, is indicated for conditions related to estrogen deficiency.

• Menopausal symptoms: alleviates hot flashes, night sweats and vaginal atrophy in post‑menopausal women.
• Ovarian failure (hypoestrogenism): restores estrogen levels in women with primary or surgical ovarian insufficiency.
• Osteoporosis prevention: reduces bone loss and fracture risk in post‑menopausal women.

• Estradiol valerate is a prodrug that is hydrolyzed after intramuscular injection to estradiol. The resulting estradiol binds to estrogen receptors ERα and ERβ, modulating transcription of estrogen‑responsive genes. This restores estrogenic activity in target tissues, influencing the hypothalamic‑pituitary‑gonadal axis, bone remodeling, and genital tract mucosa, thereby correcting estrogen deficiency.

Neofollin may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Headache: transient cranial discomfort.
• Breast tenderness: swelling or pain in breast tissue.
• Vaginal bleeding or spotting: irregular uterine bleeding.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Stroke or myocardial infarction: cardiovascular complications.
• Endometrial hyperplasia or carcinoma: abnormal uterine lining growth.

Before prescribing Neofollin, clinicians should consider several precautionary measures to ensure safe use.

• History of thromboembolic disease: avoid use in patients with prior clotting disorders.
• Cardiovascular risk: assess for hypertension, smoking, or hyperlipidemia before treatment.
• Liver function: monitor hepatic impairment as estrogen metabolism may be altered.
• Hormone‑dependent tumors: contraindicated in active breast or endometrial cancer.
• Pregnancy and lactation: avoid in women who are pregnant or breastfeeding.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Estradiol valerate can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): increased risk of thrombosis.
• Aromatase inhibitors: antagonize estrogenic effects.
• Certain antiepileptics (e.g., carbamazepine, phenytoin): reduce estradiol levels.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise estradiol concentrations.
• CYP3A4 inducers (e.g., rifampin, St. John’s wort): may lower estradiol exposure.
• Thyroid hormones: estrogen may increase thyroxine binding, requiring dose adjustment.